Abstract
Glucagon-like peptide-1 (GLP-1) is involved in satiety control and glucose homeostasis. Besides, GLP-1 has cardiovascular effects. In experimental models, GLP-1 increases cardiac output and exerts a direct vasodilatory effect. In animals with dilated cardiomyopathy GLP-1 improves left ventricular performance. Human data demonstrated that GLP-1 reduces arterial blood pressure, improves endothelial function in individuals with diabetes and left ventricular function in patients with heart failure. Administration of GLP-1 increases ejection fraction in acute myocardial infraction and reduces ischemia-reperfusion myocardial injury. Although more research is needed, these data suggest that GLP-1 may be used with promising results in patients with heart failure, acute myocardial infarction and revascularization procedures in addition to the standard therapy.
Keywords: Arterial blood pressure, cardiovascular, endothelium, glucagon-like peptide 1, heart failure, left ventricular function, type 2 diabetes mellitus, GLP-1, T2DM, cell proliferation, insulin resistant and hyperlipidemic, glomerulosclerosis, angiotensin II, Bilateral vagotomy, hyperglycemia, dilated cardiomyopathy, norepinephrine, cediranib, thrombolysis, angioplasty, low-flow ischaemia, flow mediated vasodilatation, LVEF, acetylcholine, acute occlusive ischemia
Mini-Reviews in Medicinal Chemistry
Title: Cardiovascular Effects of Glucagon-Like Peptide 1
Volume: 11 Issue: 1
Author(s): A. Papazafiropoulou, S. I. Pappas, D. Papadogiannis and N. Tentolouris
Affiliation:
Keywords: Arterial blood pressure, cardiovascular, endothelium, glucagon-like peptide 1, heart failure, left ventricular function, type 2 diabetes mellitus, GLP-1, T2DM, cell proliferation, insulin resistant and hyperlipidemic, glomerulosclerosis, angiotensin II, Bilateral vagotomy, hyperglycemia, dilated cardiomyopathy, norepinephrine, cediranib, thrombolysis, angioplasty, low-flow ischaemia, flow mediated vasodilatation, LVEF, acetylcholine, acute occlusive ischemia
Abstract: Glucagon-like peptide-1 (GLP-1) is involved in satiety control and glucose homeostasis. Besides, GLP-1 has cardiovascular effects. In experimental models, GLP-1 increases cardiac output and exerts a direct vasodilatory effect. In animals with dilated cardiomyopathy GLP-1 improves left ventricular performance. Human data demonstrated that GLP-1 reduces arterial blood pressure, improves endothelial function in individuals with diabetes and left ventricular function in patients with heart failure. Administration of GLP-1 increases ejection fraction in acute myocardial infraction and reduces ischemia-reperfusion myocardial injury. Although more research is needed, these data suggest that GLP-1 may be used with promising results in patients with heart failure, acute myocardial infarction and revascularization procedures in addition to the standard therapy.
Export Options
About this article
Cite this article as:
Papazafiropoulou A., I. Pappas S., Papadogiannis D. and Tentolouris N., Cardiovascular Effects of Glucagon-Like Peptide 1, Mini-Reviews in Medicinal Chemistry 2011; 11 (1) . https://dx.doi.org/10.2174/138955711793564033
DOI https://dx.doi.org/10.2174/138955711793564033 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antiapoptotic Effect of Novel Compound from Herba leonuri-Leonurine (SCM-198): A Mechanism Through Inhibition of Mitochondria Dysfunction in H9c2 Cells
Current Pharmaceutical Biotechnology The Role of Obesity in Cardiomyopathy and Nephropathy
Current Pharmaceutical Design Development of Doxorubicin Quantification by Reductive Amination
Current Analytical Chemistry Modulation of Fatty Acids Oxidation in Heart Failure by Selective Pharmacological Inhibition of 3-Ketoacyl Coenzyme-A Thiolase
Current Clinical Pharmacology Myocardial Regeneration: What is the Best Approach?
Current Cardiology Reviews Diagnostic and Therapeutic Nanoparticles in Cardiovascular Diseases
Current Pharmaceutical Design What Does a Pediatrician Need to Know About Chronic Diarrhea?
Current Pediatric Reviews Splice Modification to Restore Functional Dystrophin Synthesis in Duchenne Muscular Dystrophy
Current Pharmaceutical Design Early Occurrence Cases of Diabetes Mellitus: Clinical Picture in Two Major Tertiary Care Hospitals in India
Current Diabetes Reviews Microvascular Function/Dysfunction Downstream a Coronary Stenosis
Current Pharmaceutical Design Alzheimer Disease and Diabetes Mellitus: Do They have Anything in Common?
Current Alzheimer Research Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases
Current Pharmaceutical Design Phytochemicals as Prototypes for Pharmaceutical Leads Towards Drug Development Against Diabetic Cardiomyopathy
Current Pharmaceutical Design Plasma Glucose Concentrations and Cardiac Hypertrophy in Essential Hypertension
Current Hypertension Reviews Models and Methods in Cardiac Imaging for Metabolism Studies
Current Pharmaceutical Design Quantitative Analysis in Cardiovascular Imaging: Current Status
Current Medical Imaging Pharmacological Modulations of the Renin-Angiotensin-Aldosterone System in Human Congestive Heart Failure: Effects on Peripheral Vascular Endothelial Function
Current Vascular Pharmacology Chemistry, Physiology, and Pharmacology of β-Adrenergic Mechanisms in the Heart. Why are β-Blocker Antiarrhythmics Superior?
Current Pharmaceutical Design Targeting Vascular Niche by Parathyroid Hormone
Current Medicinal Chemistry Heme Oxygenase-1 in Vascular Smooth Muscle Cells Counteracts Cardiovascular Damage Induced by Angiotensin II
Current Neurovascular Research